Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 2238 for “"Phase I"”.
-
Statistical design of phase I clinical trials
My MSc thesis is focused on parametric designs of Phase I clinical trials, using the continual reassessment method. A parametric model with unknown parameters is assumed. The observations are either toxic or nontoxic. Observations of toxicities are used to update the posterior distribution. Dose …
-
Nonalcoholic Steatohepatitis Alters Phase I Drug Metabolism
… mediated by these enzymes. Overall, the major phase I drug metabolizing enzymes are profoundly altered in the progression of human NASH, which may significantly increase the incidence of VDRs. Therefore, the disease state of NASH should be taken into consideration in dosage recommendations and …
-
Cluster_Based Profile Monitoring in Phase I Analysis
… Profile monitoring is conducted over two phases, labeled as Phase I and Phase II. In Phase I profile monitoring, regression methods are used to model each profile and to detect the possible presence of out-of-control profiles in the historical data set (HDS). The out-of-control profiles …
-
Novel statistical designs for phase I clinical trials
… new drug or medical intervention. There are four phases of a clinical trial. Phase I trial is the first step to determine the maximum tolerated dose (MTD) to be used in the subsequent trials. My Ph.D. research is focused on proposing and evaluating statistical designs of Phase I clinical trial. …
-
Bayesian Phase I Dose Finding In Cancer Trials
This dissertation explores phase I dose-finding designs in cancer trials from three perspectives: the alternative Bayesian dose-escalation rules, a design based on a time-to-dose-limiting toxicity (DLT) model, and a design based on a discrete-time multi-state (DTMS) model. We list alternative …
-
Psychischer Distress bei Patienten in onkologischen Phase-I-Studien
… Distress von Patienten, die an onkologischen Phase I Studien teilnahmen sowie die Identifizierung möglicher Einflussfaktoren wie demographische Aspekte und Zufriedenheit mit der medizinischen Versorgung. Dafür wurden zu zwei Zeitpunkten Daten erhoben. Das Niveau des Distress erwies sich wie …
-
Statistical methods for efficient Phase I dose escalation trials
Phase I dose escalation studies are first-in-human clinical trials, often with the primary objective of identifying the treatment’s maximum tolerated dose (MTD). This objective is complicated by the intrinsically limited size, scope, and time frame of Phase I clinical trials. In this dissertation …
-
CLINICIANS’ JUDGMENT TO RECOMMEND PHASE I MIXED DENTITION TREATMENT
The timing and necessity of Phase I mixed dentition treatment in orthodontics have long been subjects of debate. This study aims to explore the level of agreement among clinicians in recommending Phase I treatment, the rationales behind such decisions, and the implications for Phase II treatment. …
-
Participant experiences in phase I pediatric oncology clinical trials
Phase I clinical trials (P1Ts) are the first step in testing new medical therapies in humans, and are essential for developing new and innovative therapies for children with cancer. P1Ts are ethically controversial as they are not intended to directly benefit participants, but are particularly …
-
Bayesian adaptive designs in phase I/II clinical trials
… both toxicity and efficacy outcomes in a blended phase I/II fashion. A further challenge arises when all the true efficacy data cannot be obtained quickly after the treatment, so that surrogate markers are instead used (e.g, in cancer trials). In this thesis, we first propose a framework to …
-
Dual-Criterion Dose Finding Designs for Phase I Clinical Trials
The primary objective of Phase I oncology trials is to assess the safety and tolerability of novel therapeutics. Conventional dose escalation methods identify the maximum tolerated dose (MTD) based on dose-limiting toxicity (DLT). However, as cancer therapies have evolved from chemotherapy to …
-
Culvert Roughness Elements for Native Utah Fish Passage: Phase I
Culverts can increase stream velocities as a result of reduced waterway areas and prevent upstream passage of small non-salmonid fish such as the Native Utah Leatherside chub (Gila copei) and Longnose dace (Rhinichthyscataractae). To mitigate this problem, current culvert design standards for fish …
-
Phase I and II biotransformation in patients with chronic fatigue
This thesis, titled: 'Phase I and II biotransformation in patients with chronic fatigue', forms part of the research and development programme of the Centre for Human Metabolomics at the NWU. There is no consensus definition of fatigue, ranging from idiopathic chronic fatigue (CF) to the more …
-
BLAST DAMAGE MITIGATION IN SUBMERGED SYSTEMS. PHASE I: INTERNAL EXPLOSION
… this effort represents the first of a multi-phase comprehensive research program that is focused on developing blast damage mitigation techniques in submerged structures. A confined explosion occurrence inside such facilities may lead to paralyzing all operations depending on the functions of …
-
ADVANCED REFLECTION SEISMIC STUDIES OF PHASE I WEYBURN CO2 SEQUESTRATION MONITORING
… seismic datasets and well logs collected for Phase I CO2 sequestration project in Weyburn oilfield (southern Saskatchewan, Canada) are utilized for developing new approaches in three research areas: 1) estimation of seismic source waveforms, 2) evaluation of TL acoustic impedance (AI) …
-
Alter, Muskelkraft und Muskelmasse in der Phase I der SWICOS-Studie
Hintergrund: Die Muskelkraft respektive Muskelmasse ist eine der wichtigsten pathophysiologischen Determinanten bei chronischen Erkrankungen. Die Erhaltung der Muskelkraft bzw. Muskelmasse im Alter ist daher von zentraler präventiver Bedeutung. In dieser Arbeit sollen die Abnahme der Muskelkraft …
-
Bayesian Semi-Mechanistic Dose-Finding Designs For Phase I Oncology Trials
… rates of clinical cancer drug development from phase I to III trials call for further improvements on novel designs, in addition to the need to promote and adopt novel designs in practice. Because anticancer agents often have a narrow therapeutic index, an accurate identification of the maximum …
Page 1 of 112